Investment in HPV biomarker immunoassay
Investors in biotech innovator Abviris Deutschland are injecting almost two million Euros to speed up expansion, after promising results for its immunoassay biomarker for the early diagnosis of cancers caused by human papillomavirus (HPV).
The Abviris biomarker incorporated into its CE-marked Prevo-Check point-of-care (POC) system focuses on HPV16, the most aggressive of all HPV strains and responsible for more than 90% of all HPV-related head and neck tumours, and for over half of cervical cancer cases. It relies on detecting an immune response that only occurs when HPV infection has triggered tumour growth. This is the first available blood-based test shown to be specific enough to aid in diagnosis
The company is already spearheading the development of further POC applications for the immunoassay technology, designed to address the clinical needs of other high-risk HPV types. Dr. Roman Niedbal, the company’s new CEO, explained: “Abviris is on the cusp of major expansion, with this pivotal study drawing immediate attention from potential partners and clinicians keen to collaborate.
Other News
Featured Supplier
ScheBo® • Biotech AG is an innovative biotech company that is active in the field of development, production and marketing of diagnostics.
The manufacturing of our leading products is matched exactly to satisfy of our customers.
ScheBo® • Biotech AG was founded by the biochemists and molecular biologists Ursula Scheefers-Borchel, Ph.D.,...
Upcoming Events
COVID-19 - The Infection Challenging the World
Online
11-14 May 2021
Lab Innovations 2021
NEC, Birmingham
3-4 November 2021
IBMS Biomedical Science Congress 2022
International Convention Centre, Birmingham
14-17 March 2022
Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.
Download the FREE Pathology In Practice app from your device's App store
